Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $6.6 million
April 06, 2020
Lead Product(s) : Belinostat
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Acrotech Biopharma
Deal Size : $6.6 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
